Skip to Content

Insider Trading: A director of Moderna, Inc. (NASDAQ:MRNA) has sold 10,000 shares of stock.

Insider Trading: A director of Moderna, Inc. (NASDAQ:MRNA) has sold 10,000 shares of stock.

The director of Moderna, Inc., Noubar Afeyan, sold 10,000 shares of the company’s stock on January 4 (NASDAQ: MRNA). As a result, there was a total of $1,821,500.00 worth of the company’s shares traded at an average price of $182.15 per share, which resulted in revenue of $1,821,500.00 generated by the business. As a direct consequence of the transaction, the director is now the direct owner of a total of 2,267,209 shares of the company. These shares have a combined value of $412,972,119.35. You will be taken to the legal file presented to the Securities and Exchange Commission if you click the link. In this file, the transaction is described in greater detail.
In addition, Noubar Afeyan has been involved in the following transaction(s) over the recent few days:
Friday’s trading session resulted in an increase of $6.84 in the price of a share of mRNA, which now stands at $180.35. The total number of shares of the company’s stock that changed hands was 3,479,324, which is higher than the typical volume of trading, which is 3,373,096 shares. The current price of a share of Moderna, Inc. places it at a one-year high of $241.99, while the current price of a share places it at a one-year low of $115.03. There is a ratio of 0.05 debt to equity, 1.80 quick ratios to current ratio, and 2.10 current ratio to quick ratio. The ratio of debt to equity is very low. The moving average of the company’s stock price over the past 200 days is $157.59, while the moving average over the last 50 days is $179.12. Currently, the company has a price-to-earnings ratio of 6.52, a beta value of 1.71, and a market capitalization of $69.29 billion.
Investors were given access to the most recent quarterly results report for Moderna (NASDAQ: MRNA) on the day of its public release, which was November 3. The company reported earnings per share of $2.53, which was $0.51 less than the consensus estimate of $3.04 among industry analysts. The return on equity for Moderna was 70.03 percent, and the company’s net margin was 55.00 percent of revenue. The revenue for the quarter came in at $3.36 billion, which is significantly higher than the average prediction of $3.33 billion made by the marketer 3rd. The company reported earnings per share of $2.53, which was $0.51 less than the consensus estimate of $3.04 among industry analysts. The return on equity for Moderna was 70.03 percent, and the company’s net margin was 55.00 percent of revenue. The revenue for the quarter came in at $3.36 billion, which is significantly higher than the average prediction of $3.33 billion made by the market. Professionals in equity research predict that Moderna, Inc. will finish the current fiscal year with a profit per share of 21.44 dollars.
Recent months have seen the publication of several studies dealing with mRNA. In a report made public on October 20, Cowen indicated that the price objective it had established for Moderna shares had decreased from $165.00 to $145.00. The price objective that Bank of America has placed on Moderna shares has increased from $160.00 to $182.00, as stated in a report published on November 15. Piper Sandler upgraded the stock’s rating to “overweight” and raised their target price for Moderna stock from $214.00 to $217.00 in a research note published on Tuesday, December 20. Both of these alterations were brought about as a direct reaction to recent happenings in the market. Morgan Stanley raised their price objective on shares of Moderna on Friday, December 16, announcing that they were doing so in a research note that was made public. The new price objective is $209.00 per share, up from $170.00 per share previously. In addition to that, they ranked the stock as “equal weight,” which is a neutral rating. JPMorgan Chase & Co. decreased their target price on Moderna shares from $165.00 to $120.00 and gave the company a “neutral” rating in a research report published on Monday, October 24. The company was the focus of the study. Five equity research analysts have issued a recommendation to purchase company shares, while seven analysts have advised investors to maintain their current company stock holdings. According to Bloomberg.com, the current recommendation for Moderna is “Hold,” and the consensus price target for the company is currently set at $187.86.
In the most recent few months, several hedge funds and institutional investors have altered how they hold mRNA, which can be seen as a positive development. During the second quarter, Total Clarity Wealth Management Inc. made a new investment in Moderna by purchasing approximately 2500 shares for a total value of approximately $25,000. The value of Evoke Wealth LLC’s Moderna holdings increased by 100.8% during the third quarter compared to the previous quarter. Evoke Wealth LLC now has 239 shares of the company’s stock, valued at $28,000, after purchasing an additional 120 shares during the period in question. During the third quarter, The Guardian Wealth Advisors LLC paid approximately $28,000 to purchase a new position in Moderna. During the first three months of this year, Oliver Lagore Vanvalin Investment Group spent approximately $30,000 to acquire an additional stake in Moderna. One last interesting nugget of information is that during the second quarter, FinTrust Capital Advisors LLC saw a 754.5% increase in the value of its holdings in Moderna. After purchasing an additional 166 shares during the relevant period, FinTrust Capital Advisors LLC has 188 shares of the company’s stock, currently valued at $31,000. During the relevant period, these 166 shares were acquired. Institutions own the company’s equity to 63.11%.
In the United States, Europe, and other countries, the biotechnology company Moderna, Inc. discovers, develops, and commercializes messenger RNA therapeutics and vaccines to treat infectious illnesses, immuno-oncology, uncommon diseases, cardiovascular problems, and autoimmune diseases. Its respiratory vaccines include COVID-19, influenza, respiratory syncytial virus, endemic HCV, and hMPV+PIV3. Among its latent vaccines are cytomegalovirus, Epstein-Barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus. And finally, among its public health vaccines are those for Zika and Nipah.

Leave a comment

Your email address will not be published. Required fields are marked *